Gut-acting drugs for lowering cholesterol.

被引：13

作者：

Black D.M. ^{[1
]}

机构：

[1] Medical Research Laboratories International, Highland Heights, 2 Tesseneer Avenue, 41076, KY

来源：

Current Atherosclerosis Reports | 2002年 / 4卷 / 1期

关键词：

Cholesterol; Bile Acid; Simvastatin; Fenofibrate; Ezetimibe;

D O I：

10.1007/s11883-002-0065-8

中图分类号：

学科分类号：

摘要：

Drugs that indirectly lower blood cholesterol through their actions in the gut have been used for many years. Their utility has been limited by poor tolerability, and hence, poor compliance. New resins are better tolerated and offer an advantage to older drugs. New strategies focusing on reducing serum cholesterol by acting on the gastrointestinal tract may hold even greater promise, combining the safety of nonsystemic agents with the acceptance of statins.

引用

页码：71 / 75

页数：4

共 23 条

[1]

Buchwald H(1998)Effective lipid modification by partial ilial bypass reduced long-term coronary heart disease mortality and morbidity: five year post-trial follow-up report from the POSCH Arch Intern Med 158 1253-1261

[2]

Varco RL(1971)Interruption of the enterohepatic circulation of bile acids in man: comparative effects of cholestyramine and ileal exclusion on cholesterol metabolism J Lab Clin Med 78 94-121

[3]

Boen JR(1999)Colesevalam hydrochloride (Cholestagel) a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects Arch Intern Med 159 1893-1900

[4]

Grundy SM(2001)Efficacy and safety of combination simvastatin and colesevalem in patients with primary hypercholesterolemia Am J Med 110 352-360

[5]

Ahrens EH(2001)Coadministration of colesevalem hydrochloride with atorvastatin lowers LDL cholesterol additively Atherosclerosis 158 407-416

[6]

Salen G(2000)Drug interactions of colesevalem hydrochloride, a novel, potent bile acid binding polymer Cardiovasc Drug Ther 14 681-690

[7]

Davidson M(2001)Ezetimibe: a selective inhibitor of cholesterol absorption Eur Heart J Suppl Suppl E E6-E10

[8]

Dillon MA(2001)Ezetimibe reduces low-density lipoprotein cholesterol: results of a phase III, randomized, double-blind, placebo-controlled trial Atherosclerosis 2 38-38

[9]

Gordon B(2001)Results of phase I/II clinical trials with ezetimibe, a novel selective cholesterol absorption inhibitor Eur Heart J Suppl Suppl E E11-E16

[10]

Knapp HH(undefined)undefined undefined undefined undefined-undefined

← 1 2 3 →